KidKraft Announces Appointment of Todd Whitbeck as Chief Financial Officer
KidKraft, Inc. (“KidKraft”) announced today Todd Whitbeck, a seasoned executive with more than 30 years of experience in finance and corporate development, has been appointed Chief Financial Officer effective immediately.
Whitbeck has a proven track record of financial expertise and operational leadership across a diverse background of public and private companies, with previous success working with MidOcean Partners, the private equity firm that owns KidKraft. He will oversee global financial operations and work closely with KidKraft’s CEO on continued growth and international expansion as the company builds on a 50-year legacy in the toy and juvenile product industry. Whitbeck will report directly to Geoff Walker, Chief Executive Officer.
“Todd is a seasoned finance executive and his leadership will help drive KidKraft’s growth strategies,” said Geoff Walker, CEO, KidKraft. “I’m excited for his partnership and to welcome him as a key member of our executive team.”
“I look forward to working with Geoff and the team at KidKraft and to leveraging my prior experience to fuel the company’s growth,” said Todd Whitbeck. “Having worked across many industries throughout my career, it’s refreshing after all these years to work with a company that inspires the imaginations of children who will lead future generations.”
Whitbeck was most recently CFO and Head of Business Development, Sales, Marketing and Administrative Functions for CANarchy, a fast-growing collective of local, regional and national craft beer breweries. Previously he was Executive Vice President, CFO & Business Development for Water Pik, Inc. where he led and facilitated a very successful sale of the company, and subsequently led integration efforts for the combined companies. He was CFO for JP Energy, Sears Holdings Corporation (SHC) in the hard goods business units and off-mall retail selling formats, and CompUSA, where he elevated his oversight to CFO through various finance roles as the company grew and was acquired. He is a board member for Tufts Health Plan Board of Directors.
An industry leader in design and development of children’s toys and furniture, KidKraft is focused on inspiring imaginative play experiences through high quality products. The company's innovative portfolio includes dollhouses, play kitchens, outdoor playsets, children's furniture, wooden dolls and vehicles and more, offering a variety of different play experiences this holiday season. The company was acquired by MidOcean Partners (“MidOcean”), a premier middle market private equity firm focused on consumer and business services, in July 2015.
About KidKraft, Inc.
KidKraft is a global leader in award-winning products that are MADE FOR MAKE BELIEVE™. The company is committed to inspiring imaginative play creatively for children everywhere through dollhouses, kitchens, outdoor, vehicles, furniture, and toys. KidKraft’s high-quality products, designed for traditional play, are available at more than 2,800 retailers in more than 90 countries worldwide. KidKraft’s global headquarters are located in Dallas, Texas. For more information, visit www.kidkraft.com and follow @kidkrafttoys on Instagram.
About MidOcean Partners
MidOcean Partners is a premier New York-based alternative asset manager that specializes in middle market private equity and alternative credit investments. Since its inception in 2003, MidOcean Private Equity has managed approximately $4.8 billion of committed capital and has targeted investments in high-quality middle market companies in the consumer and business services sectors. MidOcean Credit Partners was launched in 2009 and manages approximately $8 billion across a series of alternative credit strategies, collateralized loan obligations (CLOs), and customized separately managed accounts as of September 30, 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005062/en/
Contact information
Litzky Public Relations on behalf of KidKraft
Kelsey Wheeler
Litzky Public Relations
201/222-9118
kidkraft@litzkypr.com
MidOcean Media Relations
Nathaniel Garnick/Amanda Klein
Gasthalter & Co.
212/257-4170
midocean@gasthalter.com
MidOcean Investor Relations
Allison Donohue
Investorrelations@midoceanpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 10:05:00 EET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom